Strategically located in South Delhi, the newly inaugurated centre offers comprehensive fertility care under one roof by combining experienced fertility specialists, advanced reproductive medicine, and Gaudium IVF's standardized clinical protocols. The centre is built around the Gaudium Signature Lab, the company's proprietary laboratory framework that integrates advanced embryology, artificial intelligence-powered technologies, and globally recognized quality standards to create an optimal environment for embryo development. As the company expands its network, the Signature Lab model will be replicated across every new centre to ensure patients receive the same standards of precision, safety, and clinical excellence regardless of location.
The new facility also introduces Gaudium IVF's artificial intelligence-powered embryology ecosystem, including the Sperm Identification Device for advanced sperm assessment and the Embryo Ranking Intelligent Classification Assistant for embryo evaluation. These technologies complement the expertise of embryologists by providing data-driven insights that enhance precision, consistency, and confidence throughout the in vitro fertilization process.
Built on a 17-year legacy of innovation and patient-focused care, Gaudium IVF has established itself as one of India's trusted fertility care providers. The company's commitment to laboratory excellence has received international recognition through the European Quality Award from the European Society for Quality Research in Spain. The recognition reflects the high clinical standards that support the organization's treatment outcomes, including complex infertility and recurrent in vitro fertilization failure cases.
Commenting on the launch, Dr. Manika Khanna, Chairperson and Managing Director of Gaudium IVF, said that fertility care is one of the most specialized fields of medicine where science, clinical expertise, and ethical practices come together to help couples achieve parenthood. She stated that every patient deserves care that is clinically advanced, transparent, compassionate, and tailored to individual needs.
Dr. Khanna further said that the launch of the South Extension centre reflects the company's commitment to making world-class fertility care more accessible without compromising the standards that have guided the organization for the past 17 years. She added that as the company expands its network, it will continue to establish centres that combine scientific excellence, artificial intelligence-powered innovation, and globally benchmarked laboratory standards with a patient-first approach. According to her, the Gaudium Signature Lab brings together qualified embryologists, technologically advanced laboratory infrastructure, ethical medical practices, and evidence-based treatment to support informed clinical decisions while delivering the highest standards of fertility care. She emphasized that these principles will continue to guide every stage of the company's expansion.
The launch comes at a time when demand for specialized fertility care is increasing across India due to delayed parenthood, changing lifestyles, and growing awareness of assisted reproductive technologies. Through its planned network expansion, Gaudium IVF aims to replicate its Signature Lab model across all new centres by combining advanced reproductive medicine, artificial intelligence-powered embryology, and standardized clinical protocols to deliver consistent, high-quality fertility care on a larger scale while strengthening its leadership position in India's rapidly evolving fertility care sector.
Founded in 2009, Gaudium IVF and Women Health Limited has developed a nationwide presence with an expanding international footprint. Following its listing as India's first publicly listed IVF chain, the organization has continued to advance reproductive healthcare through innovation. Under the leadership of Dr. Manika Khanna, the company has focused on patient-centered care, clinical excellence, and continuous innovation in reproductive medicine. With the introduction of artificial intelligence-led embryology and the launch of the Gaudium Signature Lab, the company has taken another significant step toward expanding access to advanced fertility treatment while maintaining consistent standards of quality, safety, and ethical clinical care across its growing network.
About The Author
Comment List